Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
30
CNCR Quote, Financials, Valuation and Earnings
Last price:
$12.39
Seasonality move
:
-2.56%
Day range:
$12.23 - $12.35
52-week range:
$11.87 - $17.96
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
547
Avg. volume:
3.1K
1-year change:
-5.73%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
$12.35 | -- | -- | -- | $0.00 | 0% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$60.56 | -- | -- | -- | $0.00 | 0% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$27.21 | -- | -- | -- | $0.13 | 1.65% | -- |
|
SURI
Simplify Propel Opportunities ETF
|
$15.86 | -- | -- | -- | $0.68 | 20.74% | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
$90.82 | -- | -- | -- | $0.08 | 0.37% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$43.41 | -- | -- | -- | $0.15 | 1.56% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 2.118 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.316 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 1.073 | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | 1.741 | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.413 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 1.021 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Range Cancer Therapeutics ETF vs. Competitors
-
Which has Higher Returns CNCR or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About CNCR or BBP?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is CNCR or BBP More Risky?
Range Cancer Therapeutics ETF has a beta of 0.903, which suggesting that the stock is 9.71% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.32%.
-
Which is a Better Dividend Stock CNCR or BBP?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or BBP?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns CNCR or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About CNCR or FTXH?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is CNCR or FTXH More Risky?
Range Cancer Therapeutics ETF has a beta of 0.903, which suggesting that the stock is 9.71% less volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.157%.
-
Which is a Better Dividend Stock CNCR or FTXH?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.65% to investors and pays a quarterly dividend of $0.13 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or FTXH?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns CNCR or SURI?
Simplify Propel Opportunities ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat Simplify Propel Opportunities ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- SURISimplify Propel Opportunities ETF-- -- -- -
What do Analysts Say About CNCR or SURI?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Simplify Propel Opportunities ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than Simplify Propel Opportunities ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than Simplify Propel Opportunities ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 SURISimplify Propel Opportunities ETF0 0 0 -
Is CNCR or SURI More Risky?
Range Cancer Therapeutics ETF has a beta of 0.903, which suggesting that the stock is 9.71% less volatile than S&P 500. In comparison Simplify Propel Opportunities ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CNCR or SURI?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simplify Propel Opportunities ETF offers a yield of 20.74% to investors and pays a quarterly dividend of $0.68 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. Simplify Propel Opportunities ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or SURI?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than Simplify Propel Opportunities ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than Simplify Propel Opportunities ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while Simplify Propel Opportunities ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for Simplify Propel Opportunities ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- SURISimplify Propel Opportunities ETF-- -- -- --
-
Which has Higher Returns CNCR or XHS?
SPDR S&P Health Care Services ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About CNCR or XHS?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 XHSSPDR S&P Health Care Services ETF0 0 0 -
Is CNCR or XHS More Risky?
Range Cancer Therapeutics ETF has a beta of 0.903, which suggesting that the stock is 9.71% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.019, suggesting its more volatile than the S&P 500 by 1.88%.
-
Which is a Better Dividend Stock CNCR or XHS?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Health Care Services ETF offers a yield of 0.37% to investors and pays a quarterly dividend of $0.08 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or XHS?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns CNCR or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Range Cancer Therapeutics ETF's net margin of --. Range Cancer Therapeutics ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CNCRRange Cancer Therapeutics ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About CNCR or XPH?
Range Cancer Therapeutics ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Range Cancer Therapeutics ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Range Cancer Therapeutics ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings CNCRRange Cancer Therapeutics ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is CNCR or XPH More Risky?
Range Cancer Therapeutics ETF has a beta of 0.903, which suggesting that the stock is 9.71% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.759, suggesting its less volatile than the S&P 500 by 24.059%.
-
Which is a Better Dividend Stock CNCR or XPH?
Range Cancer Therapeutics ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.56% to investors and pays a quarterly dividend of $0.15 per share. Range Cancer Therapeutics ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNCR or XPH?
Range Cancer Therapeutics ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Range Cancer Therapeutics ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Range Cancer Therapeutics ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Range Cancer Therapeutics ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNCRRange Cancer Therapeutics ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
